SCM
AVBP icon

Soleus Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Soleus Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
+50,000
New +$1.48M 0.06% 84

Other funds holding AVBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
EFM
E Fund Management Guangzhou, China $4.46B AUM
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Soleus Capital Management's AVBP Position: Q2 2026 in Review

Soleus Capital Management opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 50,000 shares worth $1.74M. The stake represents 0.06% of the portfolio and ranks #84 among its holdings.

62 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Soleus Capital Management held 50,000 shares of ArriVent BioPharma worth $1.74M as of Q2 2026.
  • ArriVent BioPharma was a new Soleus Capital Management position in Q2 2026.
  • ArriVent BioPharma made up 0.06% of Soleus Capital Management's portfolio in Q2 2026, its #84 holding.
  • 62 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.